StonvexLoading…
StonvexStonvexStonvexCore line items from DNA's most recent SEC filings (10-K / 10-Q via EDGAR XBRL). Last 4 reporting periods.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Annual 2025 2025-12-31 | Annual 2024 2024-12-31 | Annual 2023 2023-12-31 | Annual 2022 2022-12-31 |
|---|---|---|---|---|
Revenue | $170.16M | $227.04M | $251.46M | $477.71M |
Operating Income | $-315.28M | $-559.76M | $-864.41M | $-2.21B |
Net Income | $-312.76M | $-547.03M | $-892.87M | $-2.10B |
EPS (Diluted) | $-5.64 | $-10.54 | $-18.37 | $-50.20 |
Total Assets | $1.12B | $1.38B | $1.67B | $2.54B |
Total Liabilities | $611.11M | $661.39M | $568.19M | $803.04M |
Cash & Equivalents | $167.20M | $561.57M | $944.07M | $1.32B |
Free Cash Flow OCF − CapEx | $-178.72M | $-382.13M | $-336.30M | $-304.47M |
Shares Outstanding | 58.21M | 54.37M | 50.03M | 1.89B |